Takeda teamed up with Carmine to develop gene therapy for rare diseases using a new red-blood extravehemal platform.
-
Last Update: 2020-07-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Under the terms of the agreement, Carmine Therapeutics will receive an advance payment as research funding, as well as installments totalling more than $900 million and tiered royalties.completes the preclinical validation study, Takeda has the option to obtain project authorization and will be responsible for clinical development and commercial promotion. In addition to, Takeda has provided a $5 million convertible loan to support the development of Carmine Therapeutics' new REGENT ™ platform.Carmine Therapeutics is pioneering a new therapy based on its reGENT ™ technology, using red blood cell exostos (RBCEV) (first published in Nature Communications in 2018).the priority of this therapy is non-viral gene therapy.gene therapy or repeatable administration based on erythropoietin than adeno-associated virus (AAV) -based gene therapy significantly increased (more than 11KB) and enhanced the biological distribution of targeted tissues through red blood cell outer vesylocysis surface modification..
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.